Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Kenneth Krogulski, a director at Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), has recently purchased shares in the company, according to a filing with the Securities and Exchange Commission. The transactions, conducted under a pre-established Rule 10b5-1 trading plan, took place throughout March 2025. The insider buying comes as the stock has shown remarkable performance, delivering a 244% return over the past six months and trading near $4.18, well above its 52-week low of $1.04.
Krogulski acquired a series of small blocks of common stock, totaling $4,548. The purchase prices ranged from $4.20 to $6.75 per share. Following these transactions, Krogulski’s direct ownership in the company increased to 283,718 shares. According to InvestingPro data, Cumberland Pharmaceuticals has a market capitalization of $58.32 million and maintains a moderate debt level, though it currently operates at a loss.
These acquisitions were carried out automatically as part of a trading plan adopted in November 2024, ensuring compliance with insider trading regulations. Cumberland Pharmaceuticals, based in Nashville, Tennessee, is engaged in the development and commercialization of pharmaceutical products, maintaining a healthy gross profit margin of 82.6%. For deeper insights into CPIX’s valuation and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Cumberland Pharmaceuticals reported a notable rise in Q4 2024 net revenues, reaching $10.4 million, an increase of 11.6% compared to the previous year. Despite recording a net loss of $1.9 million for the quarter, the company emphasized its commitment to innovation and market expansion. Cumberland also highlighted its plans for continued product innovation, notably with Ifitroban, and expansion of Vibativ in China. The company projects double-digit revenue growth and positive cash flow from operations in the coming year. Additionally, Cumberland Pharmaceuticals experienced a positive market response, with its stock showing significant investor optimism. The company’s strategic initiatives include acquisition efforts and clinical development programs. Analyst firms and investors are closely watching Cumberland’s progress, particularly in light of its recent developments and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.